 Imara Inc NASDAQ: IMRA shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7 absolute increase in fetal hemoglobin, or HbF, demonstrated at interim readout and the 3 responder threshold agreed to by the FDA as a potential surrogate endpoint in sickle cell disease studies. 